Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DEXTROAMPHETAMINE SULFATE

All products: general benefit

Other products in the same Health Canada class (N06BA) — coverage varies; not interchangeable

  • Lisdexamfetamine (Vyvanse): general benefit, Not a benefit
  • Methylphenidate (Foquest): general benefit, Not a benefit
  • Mixed salt amphetamine (Adderall XR): general benefit
  • Modafinil (Alertec): not a benefit

Dexedrine Spansules · DIN 01924567 · 15mg · extended release capsule

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dexedrine Spansules · DIN 01924567 Manufacturer: Paladin Pharma Inc.; listing date 2013-06-27 Health Canada: Marketed since 2026-02-25 · brand DEXEDRINE SPANSULE · ATC N06BA02 DEXAMFETAMINE · form Capsule (sustained-release) · route Oral · ingredients DEXTROAMPHETAMINE SULFATE 15 MG · company Knight therapeutics inc. · schedule Controlled drugs (cdsa i)
Check this DIN again · Health Canada product record

Ministry pays: $0.9898 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15210 · Verify on the e-Formulary ↗ (DIN 01924567)

Source record
DIN 01924567: Dexedrine Spansules Raw flags: sec3=Y Item: 282000009; group id 514; item number 1362; lccId None; manufacturer id PPI Source form: SR Cap; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $1.5222; ministry $0.9898 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01924567 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15210 Therapeutic Notes (formulary) Notes: Patients greater than 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following: 1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND 2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND 3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR, and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers. Administrative barriers include: - inability of a school to dose the child at lunch; - the school lunch hour does not coincide with the dosing schedule; - poor compliance with noon or afternoon doses; - the patient is unable to swallow tablets. Societal barriers include: - the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives; - the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Teva-Dextroamphetamine SR · DIN 02448327 · $0.9898
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:20 C.N.S. Stimulants) and how they are covered

Matched class: 28:20 C.N.S. Stimulants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MIXED SALT AMPHETAMINE Some products covered without a code (check the product listing): LISDEXAMFETAMINE DIMESYLATE, METHYLPHENIDATE HCL 28:20 C.N.S. Stimulants

LISDEXAMFETAMINE DIMESYLATE

· 60 products · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg · Cap, Chew Tab

METHYLPHENIDATE HCL

· 47 products · General benefit (43), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 25mg, 35mg, 45mg, 55mg, 70mg, 85mg, 100mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 80mg, 18mg, 27mg, 36mg, 54mg · CR Cap, ER Cap, ER Tab, SR Tab, Tab

MIXED SALT AMPHETAMINE

· 24 products · General benefit · strengths: 5mg, 10mg, 15mg, 20mg, 25mg, 30mg · ER Cap

MODAFINIL

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:20
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: an integral part of a total treatment program for adhd that may include other measures, attention deficit hyperactivity disorder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: MIXED SALT AMPHETAMINE GUANFACINE · Limited Use, codes 540 Indications Pediatrics (6 to 17 years of age) INTUNIV XR (guanfacine hydrochloride extended-release tablets) is indicated as: • monotherapy for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. PM: https://pdf.hres.ca/dpd_pm/00082036.PDF; date not captured; DIN 02409100; fetched 2026-09-10 Product monograph Need for Comprehensive Treatment Program INTUNIV XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00082036.PDF; date not captured; DIN 02409100; fetched 2026-09-10 Product monograph MIXED SALT AMPHETAMINE · General benefit Indications ADDERALL XR (mixed salts amphetamine extended-release capsules) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in: • Children (6 – 12 years of age) • Adolescents (13 – 17 years of age) • Adults (18 years of age or older) Need for Comprehensive Treatment Program ADDERALL XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081719.PDF; date 2025-09-12; DIN 02248808; fetched 2026-09-10 Product monograph ATOMOXETINE HCL · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) Need for Comprehensive Treatment Program TEVA-ATOMOXETINE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00052053.PDF; date July 2, 2019; DIN 02314541; fetched 2026-09-10 Product monograph LISDEXAMFETAMINE DIMESYLATE · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6) Need for Comprehensive Treatment Program VYVANSE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081828.PDF; date 2025-09-15; DIN 02322951; fetched 2026-09-10 Product monograph METHYLPHENIDATE HCL · General benefit (43), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) INDICATION AND CLINICAL USE pms-METHYLPHENIDATE is indicated for the treatment of:  Attention Deficit Hyperactivity Disorder (ADHD) Need for Comprehensive Treatment Program pms-METHYLPHENIDATE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00068339.PDF; date October 17, 2022; DIN 00584991; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS DEXEDRINE/DEXEDRINE SPANSULE (dextroamphetamine sulfate) is indicated: • in the adjunctive treatment of narcolepsy • for the treatment of attention deficit hyperactivity disorder (ADHD) Attention Deficit Hyperactivity Disorder (ADHD): A diagnosis of ADHD (DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and that were present before age 7 years. The symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes, lack of sustained attention, poor listener, failure to follow through on tasks, poor organization, avoids tasks requiring sustained mental effort, loses things, easily distracted, forgetful. For the Hyperactive-Impulsive Type, at least 6… https://pdf.hres.ca/dpd_pm/00083629.PDF PM date: FEB 25, 2026 Source product: DEXEDRINE; DIN 01924516; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.